Anti-Infectives: World Markets, 2nd Edition, Vol. I-III (Complete Series) : Kalorama Information

Anti-Infectives: World Markets, 2nd Edition, Vol. I-III (Complete Series)

May 1, 2007
540 Pages - Pub ID: KLI1477668

Ask a question about this report

Email a colleague

Printer format

Order by fax

Abstract

Table of Contents

Search Inside Report

Related Reports

Vol. I: Antifungals

CHAPTER ONE: Executive Summary

Introduction
Scope and Methodology
Size and Growth of the Market
Issues and Trends Affecting Market
Leading Competitors

CHAPTER TWO: Introduction

Overview
- Introduction to Pathogens
- Antimicrobial Spectrum
- Bacterial Resistance
- Principles of Anti-infective Therapy
  - Infecting Organism
  - Antibiotic Sensitivity Testing
  - Site of Infection
  - Host Defenses and Organ Function
  - Antibiotic Pharmcokinetics
  - Monitoring Therapy
- Combination Therapy and Prophylactic Use
- Fungal Infections
- Types of Fungal Infections
  - Superficial
  - Systemic
    - Histoplasmosis
    - Coccidioidomycosis
    - Blastomycosis
  - Demographics and Statistics

CHAPTER THREE: Systemic Antifungal Drugs

Overview
Description of Products
- Allylamines
- Terbinafine (Lamisil - Novartis)
- Azoles
- Fluconazole (Diflucan - Pfizer)
- Ketoconazole (Nizoral, Johnson & Johnson)
- Miconazole (Monistat, Johnson & Johnson)
- Itraconazole (Sporanox, Johnson & Johnson)
- Posaconazole (Noxafil, Schering-Plough)
- Virconazole (Vfend, Pfizer)
- Polyene Macrolides
- Amphotericin B (Ambisome, Astellas; Abelcet, Enzon; Fungizone, Apothecon).
- Griseofluvin (Fulvicin, Schering)
- Nystatin (Mycostatin, Westwood Squibb)
- Miscellaneous Antifungals
- Flucytosine (Ancoban, Valeant)
- Echinocandins
Generic Drug Impact and Availability
Research and Development
Market Size and Growth
Competitive Analysis

CHAPTER FOUR: Topical Antifungal Drugs

Overview
Description of Products
- Allylamines
- Naftifine (Naftin, Allergan)
- Terbinafine (Lamisil - Novartis)
- Butenafine (Mentax, Bertek)
- Azoles
- Miconazole (Monistat -Derm, OrthoDermatological)
- Clotrimazole (Mycelex, Bayer; Lotrimin, Schering)
- Ketoconazole (Nizoral, J&J; Xolegel, Barrier Therapeutics)
- Oxiconazole (Oxistat, GlaxoSmithKline/Elan)
- Econazole (Spectazole, Ortho Dermatological)
- Sulconazole (Exelderm, Westwood-Squibb)
- Terconazole (Terazol, Ortho Dermatological)
- Polyene Macrolides
- Nystatin (Mycostatin, Westwood Squibb)
- Miscellaneous Antifungals
- Ciclopirox (Penlac, Sanofi-Aventis/Dermik)
- Selenium sulfide (Selsun, Chattem Inc)
- Amorolfine (Loceryl, Roche)
- Alcortin (Iodoquinol, hydrocortisone, Primus Pharmaceuticals)
Generic Drug Impact and Availability
Research and Development
Market Size and Growth
Competitive Analysis

CHAPTER FIVE: Issues and Trends Affecting the Antifungal Market

Introduction
Fungal Infections and Immunocompromised Patients
Reimbursement
Infection Imaging
Expanded Use of Azoles
Drug Resistance and Interactions
Standardized Susceptibility Testing
Generic Impact and Availability
Importance of Drug Delivery
Rx-to-OTC Switches
The Antifungal Market and Enchiocandins

chapter six: Antifungal Drugs: Total Market Size and Forecast

Overview
Total market Size and Forecast

CHAPTER SEVEN: Corporate Profiles

Introduction
Astellas Pharma Inc
Barrier Therapeutics, Inc
Johnson & Johnson Group
Merck & Company, Inc
Novartis Pharmaceuticals Corporation
Pfizer, Inc
Schering-Plough Corporation

CHAPTER EIGHT: Company Directory

table of exhibits

Chapter One: Executive Summary

Table 1-1: The World Market for Antifungal Drugs 2004-2011
Figure 1-1: The World Market for Antifungal Drugs 2004-2011

Chapter Two: Introduction

Table 2-1: Estimated World and U.S. Incidence of Fungal Infections (thousands)
Figure 2-1: Estimated World and U.S. Incidence of Leading Fungal Infections
Table 2-2: World Population by Selected Geographical Region, 2006-2050
Figure 2-2: World Population by Selected Geographical Region, 2006-2050
Table 2-3: Estimated World Population by Age and Geographical Region, 2006
Figure 2-3: Estimated World Population by Age and Geographical Region, 2006
Table 2-4: World Population at Risk for Fungal Infections, Secondary to Chronic Diseases by Selected Geographical Region, 2006
Figure 2-4: World Population at Risk for Fungal Infections, Secondary to Chronic Diseases by Selected Geographical Region, 2006

Chapter Three: Systemic Antifungal Drugs

Table 3-1: Allylamines
Table 3-2: Azoles
Table 3-3: Polyene Macrolides
Table 3-4: Miscellaneous Antifungals
Table 3-5: New Generic Drug Approvals for Systemic Antifungals, United States, 2004-2006
Table 3-6: Systemic Antifungal Drugs in Development
Table 3-7: The Market for Systemic Antifungal Drugs 2004-2011
Figure 3-1: Systemic Antifungal Drug Market 2004-2011
Table 3-8: Systemic Antifungal Drug Market by Product Type (Allylamines, Azoles, Polyene Macrolides, and Others) 2004-2010
Figure 3-2 : Systemic Antifungal Drug Market Revenues and Distribution by Product Type, 2004-2010
Figure 3-3: Systemic Antifungal Drug Market Share of Revenues by Product Type 2004-2011
Figure 3-4: Systemic Antifungal Drug Market Share by Product Type 2006 and 2011
Table 3-9: Systemic Antifungal Drug Market Estimated Products Sales by Infection Type, 2006
Figure 3-5: Systemic Antifungal Drug Market Market Share by Infection Type, 2006
Table 3-10: Systemic Antifungal Drug Market Estimated Products Sales by Geographic Region, 2006
Figure 3-6: Systemic Antifungal Drug Market Market Share by Geographic Region, 2006
Table 3-11: Systemic Antifungal Drug Market Estimated Revenues and Market Share of Leading Suppliers 2006
Figure 3-7: Systemic Antifungal Drug Market Estimated Market Share by Leading Suppliers 2006
Table 3-12: Systemic Antifungal Drug Market Projected Revenues and Market Share of Leading Suppliers 2011
Figure 3-8: Systemic Antifungal Drug Market Projected Market Share by Leading Suppliers 2011
Table 3-13: Systemic Antifungal Drug Market Estimated Sales of Top Antifungal Products 2006
Figure 3-9: Systemic Antifungal Drug Market Estimated Market Share of Top Antifungal Products, 2006

Chapter Four: Topical Antifungal Drugs

Table 4-1: Allyamines
Table 4-2: Topical Azoles
Table 4-3: Polyene Macrolides
Table 4-4: Miscellaneous Antifungals
Table 4-5: New Generic Drug Approvals for Topical Antifungals,
United States, 2004-2006
Table 4-6: Topical Antifungal Drugs in Development
Table 4-7: Topical Antifungal Drug Market, 2004-2011
Figure 4-8: Topical Antifungal Drug Market, 2004-2011
Table 4-8: Topical Antifungal Drug Market, 2004-2011
Figure 4-9: Topical Antifungal Drug Market by Product Type - Revenues, 2004-2011
Figure 4-10: Topical Antifungal Drug Market by Product Type -Percent Distribution, 2004-2011
Figure 4-4: Topical Antifungal Drug Market Share by Product Type 2006 and 2011
Table 4-9: Topical Antifungal Drug Market Estimated Products Sales by Infection Type, 2006
Figure 4-5: Topical Antifungal Drug Market Market Share by Infection Type, 2006
Table 4-10 : Topical Antifungal Drug Market Estimated Products Sales by Geographic Region, 2006
Figure 4-6: Topical Antifungal Drug Market Market Share by Geographic Region, 2006
Table 4-11: Topical Antifungal Drug Market Estimated Revenues and Market Share of Leading Suppliers 2006
Figure 4-7: Topical Antifungal Drug Market Estimated Market Share by Leading Suppliers 2006
Table 4-12: Topical Antifungal Drug Market Projected Revenues and Market Share of Leading Suppliers 2011
Figure 4-8: Topical Antifungal Drug Market Projected Market Share by Leading Suppliers 2011
Table 4-13: Topical Antifungal Drug Market Estimated Sales of Top Antifungal Products 2006
Figure 4-9: Topical Antifungal Drug Market Estimated Market Share of Top Antifungal Products, 2006

Chapter Five: Issues and Trends Affecting the

Antifungal Market
Table-5-1: New Generic Drug Approvals for Antifungals, United States, 2004-2006
Table 5-2: Selected Antifungal Rx-to-OTC Switches

Chapter Six: Antifungal Drugs: Total Market

Size and Forecast
Table 6-1: The World Market for Antifungal Drugs 2004-2011
Figure 6-1: The World Market for Antifungal Drugs 2004-2011
Table 6-2: Topical Antifungal Drug Market by Type (Topical vs Systemic) 2004-2011
Figure 6-2: The World Market for Antifungal Drugs Revenues by Type (Systemic vs Topical) 2004-2011
Figure 6-3: The World Market for Antifungal Drugs Revenues by Type (Systemic vs Topical) 2006 and 2011

Vol II: Antibacterials

Executive Summary

Introduction
Scope and Methodology
Size and Growth of the Market
Issues and Trends Affecting Market
Leading Competitors

Introduction The World Market for Anti-Infectives Volume 2:

Antibacterial Drugs
Introduction to pathogens
- Classification of Antibacterial Organisms
- Antimicrobial Spectrum
- Bacterial Resistance
- Principles of Anti-infective Therapy
- Infecting Organism
- Antibiotic Sensitivity Testing
- Site of Infection
- Host Defenses and Organ Function
- Antibiotic Pharmacokinetics
- Monitoring Therapy
- Combination Therapy and Prophylactic Use
Demographics and Statistics

Issues and Trends Affecting the Antibacterial Drug Market

introduction
Drug Resistance and Interactions
Antibiotic Abuse
Antibiotic Cycling
addressing market trends
Antibiotic use in Agriculture
Antibiotic Education
Children and Bacterial resistance
The Elderly and Bacterial Resistance
Compromised Individuals and Bacterial Resistance
Screening Hospitalized patients
Side Effects of Antibiotics
Partnerships and Alliances
Environment and Drug Resistance
Methicillin-resistant Staphylococcus Aureus (MRSA)

Cephalosporin Antibiotics

Overview
Description of Products
- First Generation Cephalosporins
- Cephalexin (Keflex, Advancis Pharmaceuticals)
- Cefazolin (Ancef, GlaxoSmithKline; Cefamezin, Astellas)
- Cefadroxil (Duricef, Bristol-Myers Squibb/Warner Chilcot)
- Second Generation Cephalosporins
- Cefuroxime (Ceftin, GlaxoSmithKline)
- Cefoxitin (Mefoxin, Merck)
- Third Generation Cephalosporins
- Cefotaximen (Claforan offered by Sanofi-Aventis)
- Cefoperazone (Cefobid, Pfizer)
- Ceftibutin (Cedax, Shionogi)
- Ceftizoxime (Cefizox, Astellas)
- Ceftriaxone (Rocephin, Roche)
- Ceftazidime (Fortaz, GlaxoSmithKline)
- Cefixime (Suprax, Wyeth/Lupin Pharmaceuticals)
- Cefpodoxime (Vantin, Pfizer)
- Fourth Generation Cephalosporins
- Cefepime (Maxipime, Bristol-Myers Squibb)
Generic Drug Impact and Availability
Research and Development
Market Size and Growth
Competitive Analysis

Macrolide Antibiotics

Overview
Description of Products
- Azithromycin (Zithromax, Pfizer; Zmax, Pfizer)
- Clarithromycin (Biaxin, Abbott Laboratories)
- Erythromycin (Erythrocin, Abbott Laboratories; EryPed, Abbott Laboratories)
- Telithromycin (Ketek, Sanofi-Aventis)
Generic Drug Impact and Availability
Research and Development
Market Size and Growth
Competitive Analysis

Penicillin Antibiotics

Overview
Natural Penicillins
Penicillinase-Resistant Penicillins
Broad -Spectrum Penicillins
Extended-Spectrum Penicillins

Description of Products

Natural Penicillins
Penicillin G (Bicillin, King Pharmaceuticals; Pfizerpen, Pfizer)
Penicillinase-resistant Penicillins
Cloxacillin (Cloxapen, GlaxoSmithKline)
Oxacillin (Bactocill, GlaxoSmithKline)
Broad-spectrum Penicillins
Amoxicillin (Augmentin, GlaxoSmithKline; Amoxil,GlaxoSmithKline)
Ampicillin (Unasyn, Pfizer)
Extended-spectrum Penicillins
Carbenicillin (Geocillin, Pfizer)
Piperacillin (Pipracil, Wyeth; Zosyn, Wyeth)
Ticarcillin (Timentin, GlaxoSmithKline)

Generic Drug Impact and Availability

Research and Development

Market Size and Growth

Competitive Analysis

Quinolone Antibiotics

Overview
Description of Products
- Ciprofloxacin (Cipro, Bayer; Proquin XR, Depomed)
- Gemifloxacin (Factive, LG Chem Ltd. and Oscient Pharmaceuticals)
- Lomefloxacin (Maxaquin, Unimed)
- Nalidixic (NegGram, Sanofi-Aventis)
- Norfloxacin (Noroxin, Merck)
- Ofloxacin (Floxin, Ortho-McNeil)
- Moxifloxicin (Avelox, Bayer; Vigamox, Alcon)
- Levofloxacin (Levaquin, Ortho-McNeil; Tavanic, Sanofi-Aventis; Cravit, Daiichi Sankyo; Quixin, Santen)
- Gatifloxacin (Zymar, Allergan/Kyorin)
- Trovafloxacin (Trovan, Pfizer)
Generic Drug Impact and Availability
Research and Development
Market Size and Growth
Competitive Analysis

Sulfonamide Antibiotics

Overview
Description of Products
Sulfisoxazole (Gantrisin Pediatric, Roche)
- Oxytetracycline/Sulfamethizole/Phenazopyridine (Urobiotic, Pfizer)
- Erythromycin ethylsuccinate and Sulfisoxazole acetyl (Pediazole, Ross)
- Dapsone (Aczone Gel, QLT USA-Tolmar Inc.)
Research and Development
Market Size and Growth
Competitive Analysis

Tetracycline Antibiotics

Overview
Description of Products
Generic Drug Impact and Availability
Research and Development
Market Size and Growth
Competitive Analysis

Other Miscellaneous Antibiotics

Overview
Description of Products
Aminoglycosides
- Amikacin Sulfate (Amikin, Bristol-Myers Squibb)
- Kanamycin Sulfate (Kantrex, Bristol-Myers Squibb)
- Neomycin Sulfate (Neo-fradin, X Gen Pharms)
- Streptomycin Sulfate (Streptomycin, Pfizer)
- Lincomycin
- Clindamycin (Cleocin, Pfizer; Clindesse, KV Pharmaceutical Company; Evoclin, Connetics Corp.; Ziana Gel, Medicis/Dow)
- Chloramphenicol
- Chloramphenicol (Chloromycetin,Pfizer)
- Glycopeptide
- Vancomycin (Vancocin, Viropharma)
- Monobactams
- Aztreonam (Azactam, Bristol-Myers Squibb)
- Carbapenems
- Imipenem/cilastatin (Primaxin, Merck)
- Meropenem (Merrem, AstraZeneca)
- Metronidazole
- Metronidazole (Flagyl, Pfizer; Pylera, Axcan; Metrogel-Vaginal, 3M Pharmaceuticals; MetroGel, Galderma)
- Antituberculars
- Rifampicin (Rifater, Sanofi-Aventis)
- Capreomycin (Capastat sulfate, Eli Lilly & Co.)
- Ethionamide (Trecator SC, Wyeth)
- Aminosalicylic acid granules (Paser Granules, Jacobus Pharmaceutical)
- Cycloserine (Seromycin, Eli Lilly & Co.)
- Antileprotics
- Dapsone (Dapsone, Jacobus)
- Oxazolidinones
- Linezolid (Zyvox, Pfizer)
- Ketolides
- Telithromycin (Ketek, Sanofi-Aventis)
- Lipopeptides
- Daptomycin (Cubicin, Cubist Pharmaceutical)
- Glycyclines
- Tigecycline (Tygacil, Wyeth)
- Generic Drug Impact and Availability
- Research and Development
- Market Size and Growth
- Competitive Analysis

Corporate Profiles

Introduction
Abbott Laboratories
AstraZeneca plc
Bayer Schering Pharma AG
Cubist Pharmaceuticals, Inc
Daiichi Sankyo Co., Ltd.
GlaxoSmithKline
Johnson & Johnson Group
King Pharmaceuticals, Inc.
Merck & Company, Inc.
Pfizer, Inc.
Roche
Sanofi-Aventis
Wyeth

Company Names and Addresses

Volume III: Antivirals

Chapter One: Executive Summary

Introduction
Scope and Methodology
Size and Growth of the Market
Issues and Trends Affecting Market
Leading Competitors

Chapter Two: Introduction

Introduction to Viruses
- Examples of Pathogenic Viruses
Virus Function and Life History
- Replication in DNA Viruses
- Replication of RNA Viruses
- Replication in Retroviruses
Host Defenses Against Viruses
Viral Ploys to Invade Host Cells and Circumvent Host Responses
- Invasion of Host Cells
- Subversion of the Immune Response
- Avoidance of Immune Detection and Attack by Killer Cells
HIV and AIDS
Demographics and Epidemiology
- Cytomegalovirus
- Hepatitis B Virus
- Hepatitis C Virus (HCV)
- Herpes
- Human Immunodeficiency Virus (HIV)
- Human Papillomavirus (HPV)
- Influenza
- Respiratory Syncytial Virus (RSV)
- Population Demographics

Chapter Three: Nucleoside Analogs, Transcriptase Inhibitors, and DNA Polymerase Inhibitors

Overview
Description of Products
- Nucleoside Reverse Transcriptase Inhibitors
- Zidovudine (Retrovir, GlaxoSmithKline)
- Didanosine (Videx, Bristol-Myers Squibb)
- Zalcitabine (Hivid, Roche)
- Lamividine(Epivir, GlaxoSmithKline; Zeffix, GlaxoSmithKline)
- Stavudine (Zerit, Bristol-Myers Squibb)
- Abacavir (Ziagen, GlaxoSmithKline)
- Nucleotide Analogue Reverse Transcriptase Inhibitors
- Tenofovir (Viread, Gilead Sciences)
- Adefovir dipivoxil (Hepsera, Gilead Sciences)
- Combination Nucleoside Reverse Transcriptase Inhibitors
- Lamivudine and Zidovudine (Combivir, GlaxoSmithKline)
- Abacavir and Lamivudine (Kivexa, GlaxoSmithKline)
- Abacavir sulfate, Lamivudine and Zidovudine (Trizivir, GlaxoSmithKline)
- Non-Nucleoside Reverse Transcriptase Inhibitors
- Nevirapine (Viramune, Boehringer Ingelheim)
- Efavirenz (Sustiva, Bristol-Myers Squibb Oncology)
- Delavirdine mesylate (Rescriptor, Agouron Pharmaceuticals)
- Emtricitabine (Emtriva, Gilead Sciences)
- DNA Polymerase Inhibitors
- Acyclovir (Zovirax, GlaxoSmithKline)
- Valacyclovir (Valtrex, GlaxoSmithKline)
- Famciclovir (Famvir, Novartis)
- Penciclovir (Denavir, Novartis)
- Ganciclovir (Cytovene, Roche)
- Ribavirin (Virazole, ICN Pharmaceuticals)
- Foscarnet (Foscavir, AstraZeneca)
- Valganciclovir (Valcyte, Hoffman-LaRoche)
- Cidofovir (Vistide, Gilead Sciences)
Research and Development
- Baraclude
- Truvada
- Telbivudine
- Viramidine
- Capravirine
- Elvucitabine
- Epzicom
- Etravirine (TMC125)
- GW5634
- MIV 150
- Pradefovir
- Reverset
- TMC278
- Valopicitabine
- Valtorcitabine
- BILR 355
- Calanolide A
- DPC 961 and DPC 963
- GW8248
- MCC-478
- MIV-310
Market Size and Growth
Competitive Analysis

Chapter Four: Protease Inhibitors

Overview
Description of Products
- Single Agents
- Saquinavir (Fortovase, Hoffman-LaRoche; Invirase, Hoffman-LaRoche)
- Nelfinavir (Viracept, Agouron Pharmaceuticals)
- Indinavir (Crixivan, Merck)
- Ritonavir (Norvir, Abbott Laboratories)
- Amprenavir (Agenerase, GlaxoSmithKline
- Fosamprenavir (Lexiva, Vertex and GlaxoSmithKline)
- Atazanavir (Reyataz, Bristol-Myers Squibb)
- Combination Protease Inhibitors
- Lopinavir and Ritonavir (Kaletra, Abbott Laboratories)
Research and Development
- Tipranavir (PNU-140690)
- GW640385 (VX-385)
- TMC-114
- BMS232632
- RO033-4649
- VX-950
Market Size and Growth
Competitive Analysis

Chapter Five: Other Antivirals

Overview
Description of Products
- Aldara
- CytoGam
- Flumadine
- Fuzeon
- Infergen
- Pegasys
- Pegasys + Copegus
- Rebetol, Rebetron
- Relenza
- RespiGam
- Symmetrel
- Synagis
- Tamiflu
- Vistide
Research and Development
- Attachment and Fusion Inhibitors
- Gene Therapies
- Integrase Inhibitors
- Maturation Inhibitors
- Zinc Finger Inhibitors
- Antisense Drugs
- Cytokines
- Other
Market Size and Growth
Competitive Analysis

Chapter Six: Issues and Trends

Introduction
Antiviral Drug Resistance
HIV Drug Cost Controversy
Antiretroviral Treatment Regimens
HIV and Women
Global Surveillance
Biochemical Prevention and Treatment of Viral Infections
New Treatment for Hepatitis C
Costs and Funding of HIV Treatment
Access to HIV/AIDS Treatment

Chapter Seven: Total Market Size and Forecast

Overview
Total Market Size and Forecast

chapter Eight: Corporate Profiles

Introduction
Abbott Laboratories
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Gilead Sciences, Inc.
GlaxoSmithKline
MedImmune, Inc.
Merck & Company, Inc.
Novartis Pharmaceuticals Corporation
Roche
Schering-Plough Corporation

APPENDIX: Company Names and Addresses
List of Exhibits
Chapter One: Executive Summary

Table 7-1: The World Market for Antiviral Drugs 2002-2009
Figure 7-1: The World Market for Antiviral Drugs 2002-2009

Chapter Two: Introduction

Table 2-1: Host Cell Receptors
Table 2-1: Estimated World and U.S. Incidence of Viral Infections
Figure 2-1: Estimated World and U.S. Incidence of Leading Viral Infections
Table 2-2: World Population by Selected Geographical Region, 2004-2050
Figure 2-2: World Population by Selected Geographical Region, 2003-2050
Table 2-3: Estimated World Population by Age and Geographical Region, 2004
Figure 2-3: Estimated World Population by Age and Geographical Region, 2004

Chapter Three: Nucleoside Analogs, Transcriptase Inhibitors, and DNA Polymerase Inhibitors

Table 3-1: Currently Available Nucleoside Reverse Transcriptase Inhibitors
Table 3-2: Currently Available Non-Nucleoside Reverse Transcriptase Inhibitors
Table 3-3: Currently Available DNA Polymerase Inhibitors
Table 3-4: Nucleoside Analogs, Transcriptase Inhibitors, and DNA Polymerase Inhibitors in Development (Product, Developer, Phase)
Table 3-5: The Market for Nucleoside Analogs, Transcriptase Inhibitors and DNA Polymerase Inhibitors 2002-2009
Figure 3-1: Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor Market 2002-2009
Table 3-6: Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor Market Estimated Products Sales by Infection Type, 2004
Figure 3-2: Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor Market Market Share by Infection Type, 2004
Table 3-7: Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor Market Estimated Products Sales by Geographic Region, 2004
Figure 3-3: Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor Market Market Share by Geographic Region, 2004
Table 3-8: Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor Market Estimated Revenues and Market Share of Leading Suppliers 2004
Figure 3-4: Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor Market Estimated Market Share by Leading Suppliers 2004
Table 3-9: Estimated Sales and Market Share of Top Nucleoside Analogs, Transcriptase Inhibitors and DNA Polymerase Inhibitors 2004
Figure 3-5: Estimated Market Share of Top Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor , 2004

Chapter Four: Protease Inhibitors

Table 4-1: Currently Available Protease Inhibitors (Type, Brand, and Manufacturer)
Table 4-2: Protease Inhibitors in Development (Product, Developer, Phase, Earliest Approval Date)
Table 4-3: The Market for Protease Inhibitors 2002-2009
Figure 4-1: Protease Inhibitor Market 2002-2009
Table 4-4: Protease Inhibitor Market Estimated Products Sales by Geographic Region, 2004
Figure 4-2: Protease Inhibitor Market Market Share by Geographic Region, 2004
Table 4-5: Protease Inhibitor Market Estimated Revenues and Market Share of Leading Suppliers 2004
Figure 4-3: Protease Inhibitor Market Estimated Market Share by Leading Suppliers 2004
Table 4-8: Protease Inhibitor Market Estimated Sales of Top Protease Inhibitors 2004
Figure 4-4: Protease Inhibitor Market Estimated Market Share of Top Protease Inhibitors, 2004

Chapter Five: Other Antivirals

Table 5-1: Currently Available Other Antivirals (Type, Brand, and Manufacturer)
Table 5-2: Other Antivirals in Development (Product, Developer, Phase, Earliest Approval Date)
Table 5-3: The Market for Other Antivirals 2002-2009
Figure 5-1: The Market for Other Antivirals 2002-2009
Table 5-4: The Market for Other Antivirals Estimated Products Sales by Infection Type, 2004
Figure 5-2: The Market for Other Antivirals Market Share by Infection Type, 2004
Table 5-5: The Market for Other Antivirals Estimated Products Sales by Geographic Region, 2004
Figure 5-3: The Market for Other Antivirals Market Share by Geographic Region, 2004
Table 5-6: The Market for Other Antivirals Estimated Revenues and Market Share of Leading Suppliers 2004
Figure 5-4: Other Antiviral Market Estimated Market Share by Leading Suppliers 2004
Table 5-7: Other Antiviral Market Estimated Sales of Other Antiviral Products 2004
Figure 5-5: Other Antiviral Market Estimated Market Share of Top Other Antiviral Products, 2004

Chapter Six: Issues and Trends

Table 6-1: Women (15 to 49) Living with HIV/AIDS by Region 2004
Table 6-2: Funding for HIV/AIDS
Table 6-3: Access Needs of Adults and Children with HIV by Region 2004
Table 6-4: Antiretroviral Access for HIV Infected Individuals by Region in the Developing World

Chapter Seven: Total Market Size and Forecast

Table 7-1: The World Market for Antiviral Drugs 2002-2009
Figure 7-1: The World Market for Antiviral Drugs 2002-2009
Table 7-2: World Market for Antiviral Drugs by Type 2002-2009
Figure 7-2: The World Market for Antiviral Drugs Revenues by Type 2002-2009

800.298.5603

Int'l: +1.240.747.3096

Questions?

Contact a research specialist >